Rachel K. King insider trades: Novavax (NVAX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Rachel reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 13, 2024 | NVAX | ↓ Sell | 4,150 | $9.02 | $37K | Direct | Jan 2, 2025 (20d) |
| May 19, 2021 | NVAX | ↑ Buy | 700 | $139.64 | $98K | Direct | May 21, 2021 (2d) |
| Dec 28, 2020 | GLYC | ↓ Sell | 84,176 | $3.91 | $329K | Direct | Dec 30, 2020 (2d) |
| Mar 27, 2019 | NVAX | ↑ Buy | 42,000 | $0.53 | $22K | Direct | Mar 28, 2019 (1d) |
| Mar 27, 2019 | NVAX | ↑ Buy | 22,000 | $0.53 | $12K | Indirect | Mar 28, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Rachel K. King's insider trades
Rachel K. King is a director at Novavax (NVAX). Since Mar 27, 2019, Rachel has reported 3 open-market purchases worth $132K and 2 sales worth $367K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (26 filings), option exercises (10 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NVAX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.